BOSTON, March 16 /PRNewswire/ -- PAREXEL experts will address the benefits of rigorous early phase clinical development at the 110th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), to be held at the Gaylord National Resort in National Harbor, Maryland from March 18 - 21, 2009. The focus of PAREXEL's presence at the ASCPT meeting will be to help biopharmaceutical companies understand best practice approaches for identifying and selecting the most promising new compounds earlier.
During the meeting, Klaus Franke, M.D., Clinical Research Physician, Early Phase, PAREXEL will present the poster "A Study to Validate a Capsaicin Model of Experimental Pain in Healthy Human Volunteers," co-authored with PAREXEL colleagues Matthias Grossmann, M.D., Ph.D., Vice President, Early Phase Consulting Services; Edward Neuhoff, Neurophysiologist; and Dawie Wessels, Senior Director and Early Phase Unit Head. Dr. Franke will address the use of pain modeling in early development and advantages of combining traditional pharmacodynamic methods with relevant neuroscience biomarkers to achieve the goal of alleviating pain and related symptoms. Dr. Franke will discuss how this approach to enhance exploration of safety and efficacy and pharmacokinetic analysis can be applied to a broad range of psychiatry, neuropsychopharmacology, neuroimaging, and neurophysiology clinical studies to provide greater information about Central Nervous System (CNS) treatments. The presentation will be given during Poster Session II, starting at 8:00 a.m. on Friday, March 20.
PAREXEL Early Phase experts will be available at Booth 111 in the exhibit hall to discuss how the Company's fully integrated First in Man through Proof of Concept services can help biopharmaceutical companies generate better and faster go/no go decisions about their compounds and return solid, reproducible outcomes to succeed in later-phase trials. PA
|SOURCE PAREXEL International Corporation|
Copyright©2009 PR Newswire.
All rights reserved